• <em>DHDDS</em>-related disease; biallelic missense novel variant causing major severity with an early-onset epilepsy and hyperkinetic movement disorder
• <em>SCN1A</em> Channels a Wide Range of Epileptic Phenotypes: Report of Novel and Known Variants with Variable Presentations
• A high seizure burden increases several prostaglandin species in the hippocampus of a Scn1a(+/-) mouse model of Dravet syndrome
• A Novel Case of <em>SCN1A</em> Mutation Presenting as Hyperkinetic Movement Disorder
• A quantitative cross-sectional study of the burden of caring for patients with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex-associated epilepsy in Japan
• A retrospective study of the yield of next-generation sequencing in the diagnosis of developmental and epileptic encephalopathies and epileptic encephalopathies in 0-12 years aged children at a single tertiary care hospital in South India
• A review of the direct targets of the cannabinoids cannabidiol, Δ9-tetrahydrocannabinol, N-arachidonoylethanolamine and 2-arachidonoylglycerol
• A systematic review and meta-analysis of factors related to first line drugs refractoriness in patients with juvenile myoclonic epilepsy (JME)
• A tool for Dravet syndrome-associated neuropsychiatric comorbidities evaluation (DANCE)
• Additional Results from Two Randomized, Placebo-Controlled Trials of Stiripentol in Dravet Syndrome Highlight a Rapid Antiseizure Efficacy with Longer Seizure-Free Periods
• An Update on Stiripentol Mechanisms of Action: A Narrative Review
• Assessment of aggressive behavior in Dravet syndrome: a critical look
• Autism and attention-deficit/hyperactivity disorder in children with Dravet syndrome: A population-based study
• Autism and attention-deficit/hyperactivity disorder in Dravet syndrome
• BAYESIAN NON-HOMOGENEOUS HIDDEN MARKOV MODEL WITH VARIABLE SELECTION FOR INVESTIGATING DRIVERS OF SEIZURE RISK CYCLING
• Cardiac-Specific Deletion of Scn8a Mitigates Dravet Syndrome-Associated Sudden Death in Adults
• Caregiver perceptions of the impact of Dravet syndrome on the family, current supports and hopes and fears for the future: A qualitative study
• CBD in the Treatment of Epilepsy
• Changes in pediatric referrals after the 2009 ketogenic diet consensus recommendations
• Clinicopathologic Dissociation: Robust Lafora Body Accumulation in Malin KO Mice Without Observable Changes in Home-Cage Behavior
• Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis
• Comprehensive scoping review of fenfluramine's role in managing generalized tonic-clonic seizures in developmental and epileptic encephalopathies
• Consensus panel recommendations for the optimization of EPIDIOLEX treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex
• Conventional and novel anti-seizure medications reveal a particular role for GABA_A in a North Sea progressive myoclonus Epilepsy Drosophila model
• Correlation Analysis of Multi-Scale Ictal EEG Signals in Juvenile Myoclonic Epilepsy
• Correlation between clinical phenotypes and genotypes among 46 children with SCN1A-related developmental epileptic encephalopathy
• Cost Effectiveness of Adding Fenfluramine to Standard of Care for Patients with Dravet Syndrome in Sweden
• Deciphering the Complexities of Sodium Voltage-Gated Channel Alpha Subunit 1 (SCN1A) Mutation: A Case of Intractable Epilepsy in a Five-and-a-Half-Month-Old Male
• Development and internal validation of a clinical risk score to predict incident renal and pulmonary tumours in people with tuberous sclerosis complex
• Dissecting the Shared Genetic Architecture of Common Epilepsies With Cortical Brain Morphology
• Dravet syndrome seizure frequency and clustering: Placebo-treated patients in clinical trials
• Dravet Syndrome: A Rare Form of Epilepsy
• Drug-resistant generalized epilepsies: Revisiting the frontiers of idiopathic generalized epilepsies
• Drug-resistant juvenile myoclonic epilepsy: A literature review
• Effect of Hepatic Impairment on the Pharmacokinetics of Fenfluramine and Norfenfluramine
• Effect of levodopa on pathological gait in Dravet syndrome: A randomized crossover trial using three-dimensional gait analysis
• Effectiveness of Highly Purified Cannabidiol in Refractory and Super-Refractory Status Epilepticus: A Case Series
• Efficacy and tolerability of perampanel in pediatric patients with Dravet syndrome
• Enhancing the action of serotonin by three different mechanisms prevents spontaneous seizure-induced mortality in Dravet mice
• Epilepsies
• Epilepsy and sudden unexpected death in epilepsy in a mouse model of human <em>SCN1B</em>-linked developmental and epileptic encephalopathy
• Epilepsy phenotypes across the different age-ranges in IQSEC2-related encephalopathy: An Italian multicentre retrospective cohort study
• Epilepsy, EEG and chromosomal rearrangements
• Expanding the Mutational Landscape and Clinical Phenotype of CHD2-Related Encephalopathy
• Exploring individual parent-to-parent support interventions for parents caring for children with brain-based developmental disabilities: A scoping review
• Feeding Difficulties and Gastrostomy in Dravet Syndrome: A UK-Wide Survey and 2-Center Experience
• Fenfluramine treatment in pediatric patients with Dravet syndrome reduces seizure burden and overall healthcare costs: A retrospective and observational real-world study
• Fine Mapping and Candidate Gene Analysis of Dravet Syndrome Modifier Loci on Mouse Chromosomes 7 and 8
• Fine mapping and candidate gene analysis of Dravet syndrome modifier loci on mouse chromosomes 7 and 8
• Gene replacement therapies for inherited disorders of neurotransmission: Current progress in succinic semialdehyde dehydrogenase deficiency
• Gene-gene interaction network analysis indicates CNTN2 is a candidate gene for idiopathic generalized epilepsy
• Genetic exploration of Dravet syndrome: two case report
• Genotype-phenotype associations in 1018 individuals with SCN1A-related epilepsies
• Genotypic and phenotypic characteristics of sodium channel-associated epilepsy in Chinese population
• How Has the Treatment of Polish Children with Dravet Syndrome Changed? Future Perspectives
• Identification of etiologies according to baseline clinical features of pediatric new-onset refractory status epilepticus in single center retrospective study
• Innovative drug discovery strategies in epilepsy: integrating next-generation syndrome-specific mouse models to address pharmacoresistance and epileptogenesis
• Integrating Proteomics and Transcriptomics Reveals the Potential Pathways of Hippocampal Neuron Apoptosis in Dravet Syndrome Model Mice
• Les données probantes et les recommandations sur le cannabis à des fins médicales chez les enfants
• Microglia Mitigate Neuronal Activation in a Zebrafish Model of Dravet Syndrome
• Modulating Endoplasmic Reticulum Chaperones and Mutant Protein Degradation in GABRG2(Q390X) Associated with Genetic Epilepsy with Febrile Seizures Plus and Dravet Syndrome
• Mosaicism-independent mechanisms contribute to Pcdh19-related epilepsy and repetitive behaviors in <em>Xenopus</em>
• Myoclonus improvement after seizures in progressive myoclonic epilepsy type 7: a case report
• Navigating Dravet syndrome in Spain: A cross-sectional study of diagnosis, management, and care coordination
• Ndnf interneuron excitability is spared in a mouse model of Dravet syndrome
• Off-label use of cannabidiol in genetic epileptic and developmental encephalopathies: A case report
• Opposing effects of the purinergic P2X7 receptor on seizures in neurons and microglia in male mice
• Optimal dose of fenfluramine in adjuvant treatment of drug-resistant epilepsy: evidence from randomized controlled trials
• Patient and provider attitudes regarding sudden unexpected death in epilepsy disclosure at a low-resource, minority community health center
• Perampanel for the treatment of epilepsy with genetic aetiology: Real-world evidence from the PERMIT Extension study
• Placebo response in patients with Dravet syndrome: Post-hoc analysis of two clinical trials
• Population pharmacokinetics, enzyme occupancy, and pharmacodynamic modeling of soticlestat in patients with developmental and epileptic encephalopathies
• Population-based study of rare epilepsy incidence in a US urban population
• Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice
• Predictors of genetic diagnosis in individuals with developmental and epileptic encephalopathies
• Preictal dysfunctions of inhibitory interneurons paradoxically lead to their rebound hyperactivity and to low-voltage-fast onset seizures in Dravet syndrome
• Preimplantation genetic testing for monogenic disorders (PGT-M) offers an alternative strategy to prevent children from being born with hereditary neurological diseases or metabolic diseases dominated by nervous system phenotypes: a retrospective study
• Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development
• Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). II. Drugs in more advanced clinical development
• Progressive myoclonic epilepsy: a retrospective study of newly-diagnosed adult patients from a single center
• Respiratory Syncytial Virus in a Child With Dravet Syndrome: A Case Report
• Response: Do all individuals with Dravet syndrome have intellectual disability?
• Sarcopenia and anti-seizure medication response in juvenile myoclonic epilepsy
• SCN1A intronic variants impact on Nav1.1 protein expression and sodium channel function, and associated with epilepsy phenotypic severity
• SCN1A-Characterization of the Gene's Variants in the Polish Cohort of Patients with Dravet Syndrome: One Center Experience
• Split intein converting peptide protein interaction into electrochemically assisted metal ion catalytic signal in the prenatal screening of pediatric epilepsy
• Stiripentol efficacy against status epilepticus and associated mortality in mice
• Survey of rehabilitation approaches and plans for individuals with dravet syndrome (RAPIDS) in Italy: Current practices and strategies to progress
• Testing of putative antiseizure medications in a preclinical Dravet syndrome zebrafish model
• The assessment of the impact of antiepileptic drugs on cognitive functions via N-200/P-300 potentials and neuropsychological measures
• The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet Syndrome: a narrative review of clinical trials
• The emotional burden of caring for patients with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex-associated epilepsy: A qualitative study in Japan
• The social and emotional burden of Dravet syndrome on Spanish caregivers
• The Therapeutic Role of Perampanel in Treating Pediatric Patients With Dravet Syndrome: A Scoping Review
• Therapeutic Nonsense Suppression Modalities: From Small Molecules to Nucleic Acid-Based Approaches
• Underlying Disorders in Children With Infection-Related Acute Encephalopathy
• Understanding neurodevelopmental trajectories and behavioral profiles in SCN1A-related epilepsy syndromes
• Unraveling the shared genetics of common epilepsies and general cognitive ability
• Vagus nerve stimulation for the therapy of Dravet syndrome: a systematic review and meta-analysis
• Voltage-gated sodium channel epilepsies in a tertiary care center: Phenotypic spectrum with correlation to predicted functional effects